These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 33914670)
1. Advances in the discovery of novel agents for the treatment of glaucoma. Mincione F; Nocentini A; Supuran CT Expert Opin Drug Discov; 2021 Oct; 16(10):1209-1225. PubMed ID: 33914670 [TBL] [Abstract][Full Text] [Related]
2. Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma. Lu LJ; Tsai JC; Liu J Yale J Biol Med; 2017 Mar; 90(1):111-118. PubMed ID: 28356898 [TBL] [Abstract][Full Text] [Related]
3. Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019). Nocentini A; Supuran CT Expert Opin Ther Pat; 2019 Oct; 29(10):805-815. PubMed ID: 31486689 [No Abstract] [Full Text] [Related]
4. Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595. Bonardi A; Supuran CT Expert Opin Ther Pat; 2019 Oct; 29(10):753-759. PubMed ID: 31438732 [No Abstract] [Full Text] [Related]
7. Discovery of novel inhibitors for the treatment of glaucoma. Cholkar K; Trinh HM; Pal D; Mitra AK Expert Opin Drug Discov; 2015 Mar; 10(3):293-313. PubMed ID: 25575654 [TBL] [Abstract][Full Text] [Related]
8. The Application of Rho Kinase Inhibitors in the Management of Glaucoma. Liu LC; Chen YH; Lu DW Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891764 [TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for ocular hypertension. Lee AJ; Goldberg I Expert Opin Emerg Drugs; 2011 Mar; 16(1):137-61. PubMed ID: 21352074 [TBL] [Abstract][Full Text] [Related]
10. Management of glaucoma: focus on pharmacological therapy. Marquis RE; Whitson JT Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346 [TBL] [Abstract][Full Text] [Related]
11. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys. Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237 [No Abstract] [Full Text] [Related]
12. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Kaufman PL Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563 [TBL] [Abstract][Full Text] [Related]
13. [Mode of action, clinical profile and relevance of carbonic anhydrase inhibitors in glaucoma therapy]. Eichhorn M Klin Monbl Augenheilkd; 2013 Feb; 230(2):146-9. PubMed ID: 23430679 [TBL] [Abstract][Full Text] [Related]
14. Medical therapy for glaucoma: what to add after a prostaglandin analogs? Tanna AP; Lin AB Curr Opin Ophthalmol; 2015 Mar; 26(2):116-20. PubMed ID: 25594765 [TBL] [Abstract][Full Text] [Related]
15. Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment. Schehlein EM; Robin AL Drugs; 2019 Jul; 79(10):1031-1036. PubMed ID: 31134520 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological therapy for glaucoma: a review. Hoyng PF; van Beek LM Drugs; 2000 Mar; 59(3):411-34. PubMed ID: 10776828 [TBL] [Abstract][Full Text] [Related]